Alkermes

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.

About ALKS

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. 

CEO
Richard F. Pops
CEORichard F. Pops
Employees
1,800
Employees1,800
Headquarters
Dublin, Dublin
HeadquartersDublin, Dublin
Founded
2011
Founded2011
Employees
1,800
Employees1,800

ALKS Key Statistics

Market cap
5.07B
Market cap5.07B
Price-Earnings ratio
15.19
Price-Earnings ratio15.19
Dividend yield
Dividend yield
Average volume
2.85M
Average volume2.85M
High today
$31.13
High today$31.13
Low today
$30.36
Low today$30.36
Open price
$30.70
Open price$30.70
Volume
2.02M
Volume2.02M
52 Week high
$36.45
52 Week high$36.45
52 Week low
$25.17
52 Week low$25.17

ALKS News

TipRanks 4d
Alkermes’ Acquisition of Avadel Faces Uncertainty Amid Regulatory and Financial Hurdles

Alkermes plc (ALKS) has disclosed a new risk, in the Corporate Activity and Growth category. Elevate Your Investing Strategy: Take advantage of TipRanks Premi...

TipRanks 5d
Alkermes price target raised to $34 from $33 at BofA

BofA analyst Jason Gerberry raised the firm’s price target on Alkermes (ALKS) to $34 from $33 and keeps a Neutral rating on the shares following what the firm c...

TipRanks 5d
Alkermes’ Strong Financial Performance and Strategic Moves Justify Buy Rating

Joseph Thome, an analyst from TD Cowen, maintained the Buy rating on Alkermes. The associated price target was raised to $40.00. Elevate Your Investing Strategy...

Analyst ratings

80%

of 15 ratings
Buy
80%
Hold
20%
Sell
0%

More ALKS News

Nasdaq 5d
Alkermes Surpasses Q3 Earnings and Revenue Estimates

Alkermes (ALKS) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.73...

Alkermes Surpasses Q3 Earnings and Revenue Estimates
Nasdaq 5d
Alkermes Plc Q3 Profit Retreats

(RTTNews) - Alkermes plc (ALKS) released earnings for third quarter that Dropped, from the same period last year The company's earnings came in at $82.76 milli...

Alkermes Plc Q3 Profit Retreats
TipRanks 6d
Alkermes’ ENLIGHTEN-Youth Study: A Potential Game-Changer in Pediatric Antipsychotic Treatment

Alkermes plc ((ALKS)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unl...

TipRanks 6d
Alkermes’ Pediatric Study on OLZ/SAM: A Long-term Safety Evaluation

Alkermes plc ((ALKS)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unl...

People also own

Based on the portfolios of people who own ALKS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.